Logo Image
News|Videos|December 4, 2024

GLP-1 RA antiobesity medications: Predictions for the future

Listen
0:00 / 0:00

Key Takeaways

  • GLP-1 RA drugs represent a major advancement in obesity treatment, indicating a paradigm shift in managing the condition.
  • New pharmacological options for obesity are expected to emerge soon, enhancing treatment possibilities.
SHOW MORE

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

GLP-1 RA drugs are an important step in changing the treatment of obesity. There is a paradigm shift in thinking about obesity, and new drugs will come in a relatively short period of time. Meanwhile, “the cost clearly has to come down,” said Robert Kushner, MD, an expert researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.

Related Content

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?
Video

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

View more